Figure 1. Detrimental effects of rs9349379-G allele on coronary microvascular function and endothelin-1. (A) Patients with G allele were over twice as likely to have underlying microvascular dysfunction (odds ratio per G allele 2.33, 95% confidence interval 1.10–4.96; P = 0.027) Even after adjustment for other risk factors the G allele was predictive of microvascular disease (odds ratio 2.31; 95% confidence interval 1.0–4.91). This finding supports a detrimental impact on the coronary microcirculation of a lifetime of increased endothelin gene expression. (B) In a multivariable regression model adjusting for baseline group differences, patients with rs9349379-G allele had higher plasma endothelin-1 (least squares mean 1.59 pg/mL vs. 1.28 pg/mL; 95% confidence interval 0.10–0.53; P = 0.005).
Figure 2. Genotype: phenotype association of G allele with invasive coronary microvascular dysfunction. (A–C) The prevalence of microvascular dysfunction detected during invasive coronary testing was associated with genotype status (AA 60%, AG 75%, GG 83%; P = 0.021). Presence of abnormal coronary flow reserve and microcirculatory resistance were linearly associated with each additional G allele. P-value represents Pearson χ2 test for linear trend (categorical data). (D) Coronary flow reserve was lower amongst subjects with two high-risk G alleles (rs9349379) consistent with detrimental effects of increased endothelin gene expression on the coronary microcirculation (Kruskal–Wallis between groups dotted line, P = 0.046). A priori subgroup analysis (AA vs. GG group—solid line) showed lower CFR in the GG group (P = 0.013). Data are median CFR plus error bars represent 95% confidence intervals for the median. P = 0.021, P = 0.030, P = 0.029 and P = 0.046.
Figure 3. Genotype: phenotype association of G allele with non-invasive ischaemia testing. (A) Cardiovascular stress magnetic resonance imaging at 1.5 T (N = 107). There was a linear relationship between the G allele and presence of an inducible perfusion defect on cardiac magnetic resonance (χ2 test for linear trend P = 0.042). (B) The relationship was more robust when considering with invasive evidence of coronary microvascular dysfunction and/or inducible perfusion defect. Over 90% of GG subjects had at least one abnormality compared with only 65% of AA subjects (P < 0.001). (C and D) Myocardial perfusion reserve was numerically reduced in AG and GG subjects compared with AA subjects; however, this was not statistically significant (P-value represents analysis of variance test for trend). Error bars represent 95% confidence intervals for the mean. (E) Invasive evidence of microvascular dysfunction (defined by abnormal response to intracoronary acetylcholine and/or systemic adenosine) was functionally significant and associated with ischaemic burden on symptom limited exercise treadmill testing (coronary microvascular dysfunction −2.3 vs. no coronary microvascular dysfunction +3.5;…
Figure 4. Endothelin-1 ex vivo vascular biology by genotype. (A) cumulative concentration response curve to endothelin-1 in the three groups in the presence and absence of ETA antagonist BQ123 (n = 44). Similar antagonist potency (rightward curve shift) for each group suggesting firstly that the ETA receptors are the dominant effectors of the endothelin-1 vasoconstrictor response and secondly that the ETA receptor pathway is not down-regulated in spite of the elevated endothelin-1 gene expression and known increase in endothelin-1 activity in the G allele single-nucleotide polymorphism patients. (B) Antagonist potency of novel therapeutic oral ETA receptor antagonist zibotentan [N = 8, mean 7.54 (95% confidence interval 7.27–7.82)] is similar to peptide antagonist BQ123 [N = 27, mean 7.53 (95% confidence interval 7.37–7.69)]. Higher pKB represents a higher antagonist potency. (C) Zibotentan: reversal of established endothelin-1 vasoconstriction. Proof of concept dose-dependent reversal of potent and established endothelin-1-mediated peripheral arteriolar vasoconstriction. Crucially, the highest concentration tested which is also the plasma concentration achieved by a clinically relevant…
Figure 5. GG (high-risk endothelin-1 gene enhancer). Illustrative case from a patient with stable angina including representative images from invasive and non-invasive work up are shown in relation to clinical presentation and endothelin-1 enhancer genotype. Maximum ST represents the maximum planar or down sloping ST-segment depression during the exercise treadmill test. Invasive coronary angiography of both subjects is near identical showing only minimal luminal irregularities. White arrows represent subendocardial inducible ischaemic myocardium during adenosine stress magnetic resonance imaging in a patient with severe coronary microvascular dysfunction. Ex vivo vascular biology (bottom panel) shows typical endothelin-1-mediated vessel constriction during wire myography. Increasing vessel tension corresponds to the rising curve at each dose titration. A paired identical vessel experiment is performed after incubation with BQ123, an ETA receptor antagonist. This curve is marked in blue, the curve of endothelin-1 response is shifted to the right indicating that the ETA receptor mediates vasoconstriction. Despite the endothelin-1 gene enhancer, the GG subject does not appear to have ETA…
We only have this paper's title and publication details.
Answers are grounded in this paper and cite their sources.
ClinicalTrials.gov: NCT03193294.
No takes yet. Share an insight, caveat, or question.
Ford et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: